{'output': [['bluebird bio Inc', 'COMP', 'Announce', 'filing for regulatory approval of three novel treatments', 'EVENT'], ['bluebird bio Inc', 'COMP', 'Operate_In', 'Biotech sector', 'SECTOR'], ['Nick Leschly', 'PERSON', 'Is_Member_Of', 'bluebird bio Inc', 'COMP'], ['bluebird bio Inc', 'COMP', 'Expects', 'filing for approval this year for its treatment for transfusion-dependent beta thalassemia', 'EVENT'], ['bluebird bio Inc', 'COMP', 'Expects', 'filing for U.S. and European approval of b2121 in 2019', 'EVENT'], ['bluebird bio Inc', 'COMP', 'Develop', 'treatment for a rare and deadly genetic brain disorder, cerebral adrenoleukodystrophy', 'EVENT'], ['bluebird bio Inc', 'COMP', 'Develop', 'promising treatment for sickle cell disease', 'EVENT'], ['bluebird bio Inc', 'COMP', 'Plan', 'discuss appropriate endpoints for future sickle cell clinical trials with health regulators', 'EVENT'], ['bluebird bio Inc', 'COMP', 'Plan', 'provide an update on the program at the end of the year', 'EVENT'], ['bluebird bio Inc', 'COMP', 'Looking', 'develop right pricing and reimbursement strategy', 'EVENT'], ['bluebird bio Inc', 'COMP', 'Has', 'two approved CAR-T treatments for other cancers from Novartis and Gilead Sciences', 'EVENT'], ['Novartis', 'COMP', 'Has', 'approved CAR-T treatment for other cancers', 'EVENT'], ['Gilead Sciences', 'COMP', 'Has', 'approved CAR-T treatment for other cancers', 'EVENT'], ['bluebird bio Inc', 'COMP', 'Principle', 'Donâ€™t do stupid shortsighted stuff', 'CONCEPT']]}